Laurion Capital Management’s Standard BioTools LAB Stock Holding History

Laurion Capital Management’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18K	Buy	+21,821	New	+$20.6K	﹤0.01%	416
2024 Q2	–	Sell	-300,010	Closed	-$813K	–	665
2024 Q1	$813K	Hold	300,010	–	–	0.01%	395
2023 Q4	$663K	Buy	+300,010	New	+$640K	0.01%	372
2022 Q3	–	Sell	-24,188	Closed	-$39K	–	548
2022 Q2	$39K	Buy	+24,188	New	+$59.8K	﹤0.01%	438
2019 Q1	–	Sell	-94,300	Closed	-$812K	–	1088
2018 Q4	$812K	Buy	+94,300	New	+$735K	0.01%	608

Other funds holding LAB

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBWM

Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Laurion Capital Management's LAB Position: Q2 2026 in Review

Laurion Capital Management opened a new position in Standard BioTools (LAB) in Q2 2026: 21,821 shares worth $18K. The stake represents ﹤0.01% of the portfolio and ranks #416 among its holdings. This is a return to the name: Laurion Capital Management previously reported a position in LAB as recently as Q1 2024.

Laurion Capital Management first reported a position in LAB in Q4 2018 and has held it in 5 quarters since. The position peaked at $813K in Q1 2024. 143 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

Laurion Capital Management held 21,821 shares of Standard BioTools worth $18K as of Q2 2026.
Standard BioTools was a new Laurion Capital Management position in Q2 2026.
Standard BioTools made up ﹤0.01% of Laurion Capital Management's portfolio in Q2 2026, its #416 holding.
Laurion Capital Management first reported a position in Standard BioTools in Q4 2018 and has held it in 5 quarters since.
Laurion Capital Management's Standard BioTools position peaked at $813K in Q1 2024.
143 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Laurion Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.